
Xilio Therapeutics fell 28.5% from $10.50 to $7.51, behind the S&P 500's +5.7%. Its worst day was May 5 (−7.4%), and its low came Mar 13 at $7.14.
Nov 20, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Xilio Therapeutics closed at its highest level of the year, 1.0% above where the year started.
+1.0% · S&P 500 +0.5%
Xilio Therapeutics shares rose 11.4%, while the S&P 500 fell 1.5%.
Story events cover the past 12 months · Times ET
+11.4% · S&P 500 −1.5%
Xilio Therapeutics closed at its lowest level of the year, 32.0% below where the year started.
−0.2% · S&P 500 −0.6%
EPS of $0.81 beat the $-0.74 estimate on $13.7M revenue (est. $8.0M).
0.0% · S&P 500 +1.1%
EPS of $-0.58 beat the $-0.66 estimate on $12.6M revenue (est. $8.5M).
0.0% · S&P 500 −0.2%
Xilio Therapeutics shares fell 7.2%, while the S&P 500 fell 2.6%.
−7.2% · S&P 500 −2.6%
EPS of $-0.33 beat the $-0.59 estimate on $18.7M revenue (est. $12.7M).
−1.4% · S&P 500 +0.3%
Xilio Therapeutics shares rose 9.6%, while the S&P 500 rose 0.6%.
+9.6% · S&P 500 +0.6%
EPS of $-0.30 beat the $-0.96 estimate on $10.0M revenue (est. $4.9M).
−5.2% · S&P 500 −0.4%
Where it ended: a close of $7.51 on Nov 19, 2026.
Nothing in the past 12 months.
All XLO dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for XLO and SPY from Benzinga historical bars. Not investment advice.